Since the advent of CAR-T therapy, it has created countless “curative miracles” in relapsed and refractory hematologic malignancies, fundamentally changing the treatment landscape for blood cancers. However, solid tumors have remained a formidable challenge for CAR-T therapy due to their complex tumor microenvironment, high heterogeneity, and immune-suppressive mechanisms. Hepatocellular carcinoma (HCC), a malignancy with high global incidence and mortality, has very limited treatment options for advanced-stage patients and a poor prognosis.

Against this backdrop, GPC3 (Glypican-3) has emerged as a key target for CAR-T therapy in solid tumors due to its highly specific expression in liver cancer cells. This presents new therapeutic hope for patients with advanced HCC and marks the next frontier for CAR-T therapy.

In the rapid development of CAR-T therapies, DengYueMed is committed to drug supply and logistics services, ensuring that innovative therapies can efficiently and compliantly reach patients worldwide.

GPC3: The Golden Target for CAR-T in Liver Cancer

GPC3 is a cell-surface oncofetal antigen primarily involved in regulating cell proliferation, differentiation, and migration. It is nearly absent in normal adult liver tissue but is highly expressed in 70%-80% of HCC patients, particularly in advanced, poorly differentiated tumors or those with distant metastases. This tumor-specific expression pattern makes GPC3 an ideal CAR-T target.

GPC3-targeted CAR-T cells can precisely recognize and bind liver cancer cells, achieving selective cytotoxicity while minimizing damage to normal liver tissue and significantly reducing off-target toxicity. This feature effectively addresses the long-standing “lack of specificity” challenge faced by CAR-T therapy in solid tumors.

Advantages of GPC3 CAR-T Therapy

Compared to conventional liver cancer treatments, GPC3 CAR-T therapy offers multiple advantages:

1.  Precision targeting: Engineered T cells are designed to specifically recognize GPC3-positive tumor cells.

2.  High efficacy: After reinfusion, modified T cells can rapidly proliferate, sustain cytotoxic activity, and form immune memory for long-term tumor surveillance.

3.  Applicable to resistant patients: Even in patients resistant to targeted drugs or immunotherapy, GPC3 CAR-T can still provide therapeutic benefit.

4.  Favorable safety profile: Clinical observations indicate mainly mild-to-moderate fever, lymphopenia, and mild cytokine release syndrome (CRS). Severe grade 3–4 neurotoxicity is rare, and liver function impairment is reversible.

Clinical Research Progress

In recent years, clinical studies of GPC3 CAR-T therapy have achieved significant breakthroughs:

● Early case reports: Cancer Communications reported two advanced HCC patients who received GPC3 CAR-T therapy. They achieved 8-year overall survival and 5-year disease-free survival, with normalization of alpha-fetoprotein (AFP) levels and complete tumor remission, marking a milestone in CAR-T therapy against solid tumors.

● Multicenter clinical trials:C-CAR031 IIT study: Among 24 advanced HCC patients who failed multiple prior treatments, the disease control rate was 90.9%, objective response rate 50%, and median intra- and extrahepatic lesion shrinkage reached 44%.

○ GC-CAR-T Phase II trial: CAR-T cells modified via CRISPR-Cas9 triple gene editing showed an objective response rate of 58%, with median survival more than double that of conventional therapy, while severe CRS incidence was significantly reduced.

These studies demonstrate that GPC3 CAR-T therapy can achieve high efficacy while maintaining controllable safety and tolerability, providing new survival opportunities for advanced HCC patients.

Major Challenges and Optimization Strategies

Despite its promising prospects, large-scale clinical application of GPC3 CAR-T therapy faces three core challenges:

1.  Tumor heterogeneity: Some patients have uneven or negative GPC3 expression, which may cause antigen escape and relapse.

2.  Immunosuppressive tumor microenvironment: Dense liver cancer stroma, abundant regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and high PD-L1 expression inhibit CAR-T infiltration and function.

3.  CAR-T delivery and persistence: Limited CAR-T cell concentration at tumor sites and short survival time make complete tumor eradication difficult.

To address these challenges, researchers are exploring the following optimization strategies:

● Dual-target or logic-gated CAR-T: Combine GPC3 with AFP, c-Met, or other targets to enhance specificity and reduce the risk of antigen escape.

● Armored CAR-T: Knock out PD-1 and secrete IL-15/CCL19 to enhance exhaustion resistance and tumor infiltration.

● Localized administration: Deliver CAR-T via hepatic artery or portal vein to increase local tumor concentration while minimizing systemic toxicity.

● Combination therapy: Combine with tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors to synergistically improve the tumor microenvironment.

Outlook

GPC3 CAR-T therapy not only represents a key leap of CAR-T technology from hematologic malignancies to solid tumors but also reshapes the treatment landscape for advanced HCC. With continued clinical research and technological optimization, GPC3 CAR-T is expected to become a first- or second-line standard therapy for advanced GPC3-positive HCC patients, offering long-term survival hope.

At the industry level, as a professional drug wholesaler and supplier, DengYuemed plays a critical role in the global promotion and clinical accessibility of GPC3 CAR-T therapy.

In the future, as technology matures and clinical evidence accumulates, DengYuemed is poised to provide continuous support in the global drug supply chain for CAR-T therapy, bringing more survival opportunities to patients worldwide.